Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

NCT03482102 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Biliary Tract Cancer

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab
RADIATION: Radiation

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]